FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy
Business Wire,
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that tafamidis received Breakthrough Therapy designation from…